Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
Rallybio Corp is a clinical-stage biotechnology company focused on developing innovative therapies for rare diseases, especially within immunology and hematology. The company boasts a promising pipeline of biologic drug candidates that are currently advancing through clinical trials, backed by an experienced management team with significant industry expertise. By forming strategic partnerships, Rallybio enhances its capacity to deliver transformative treatments in underserved therapeutic areas, demonstrating its commitment to improving patient outcomes. With a well-defined strategy and a robust developmental framework, Rallybio is strategically positioned to achieve significant milestones in the healthcare sector.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$16.75
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 6, 2026 | $-1.28 | $-1.09 | Beat +14.8% | $7.53 | $0 | $0 | — | 1D Pre+1.1% | On-Day+0.3% | 1D Post-0.2% |
Q ended Mar 31, 2026 Reported May 13, 2026 | $-1.20 | $-1.46 | Miss -21.7% | $-1.46 | $0 | $212K | — | 1D Pre+0.2% | On-Day+2.3% | 1D Post-1.0% |
Q ended Dec 31, 2025 Reported Mar 12, 2026 | $-0.15 | $-1.52 | Miss -913.3% | |||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $133.33K |
| $222K |
| +66.5% |
| 1D Pre-0.2% |
| On-Day-3.8% |
| 1D Post-1.0% |
Q ended Sep 30, 2025 Reported Nov 6, 2025 | $-1.56 | $2.88 | Beat +284.6% | — | $66.67K | $212K | +218.0% | 1D Pre-0.7% | On-Day+2.2% | 1D Post-2.1% |